Last reviewed · How we verify
GHB11L1
GHB11L1 is a therapeutic antibody targeting a viral or cellular antigen to enhance immune response against infection or disease.
At a glance
| Generic name | GHB11L1 |
|---|---|
| Also known as | A/Brisbane/59/07(H1N1)-like delNS1 virus reassortant |
| Sponsor | AVIR Green Hills Biotechnology AG |
| Modality | Biologic |
| Phase | Phase 2 |
Mechanism of action
While specific mechanistic details for GHB11L1 are limited in public literature, AVIR Green Hills Biotechnology AG focuses on viral immunotherapy and antibody-based therapeutics. The compound is likely designed to modulate immune function through antibody-mediated mechanisms, potentially targeting viral antigens or immune checkpoints relevant to infectious disease or oncology applications.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GHB11L1 CI brief — competitive landscape report
- GHB11L1 updates RSS · CI watch RSS
- AVIR Green Hills Biotechnology AG portfolio CI